Assessment of Angiogenesis in Children with Acute Lymphoblastic Leukemia Based on Serum Vascular Endothelial Growth Factor Assay

Abstract

Introduction: Vascular endothelial growth factor A (VEGFA) is a key proangiogenic cytokine. The role of angiogenesis in acute lymphoblastic leukemia (ALL) is still unclear. The purpose of the study was to assess angiogenesis in children with ALL based on serum VEGFA level determined at diagnosis and at remission with further participant subdivision into different risk groups. Materials and Methods: Forty children, aged 3–12 years (mean age: 8 years) with newly diagnosed ALL, were enrolled in the study. The control group (Group C) was twenty healthy children. According to the risk assessment, they were classified into a standard-risk group, an intermediate-risk group (IRG), or a high-risk group (HRG). Results: The median serum VEGFA levels at diagnosis were significantly higher in IRG and HRG as compared to Group C. The VEGFA levels at remission were significantly higher in all study groups, as compared to Group C. The differences in median values of serum VEGFA levels between the study groups both at diagnosis and at remission were not statistically significant. Conclusions: The angiogenesis in ALL seems to be intensified at diagnosis as a result of neoplasmatic bone marrow rebuilding and at remission as its intensive recovering.

Keywords

Acute lymphoblastic leukemia - angiogenesis - children - vascular endothelial growth factor

Publication History

Article published online:
04 July 2021

• References

• 1 Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-33.
• 2 Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, et al. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angiogenesis 2001;4:37-43.
• 3 Fukushima N, Satoh T, Sano M, Tokunaga O. Angiogenesis and mast cells in non-Hodgkin's lymphoma: A strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2001;42:709-20.
• 4 Medinger M, Passweg J. Role of tumour angiogenesis in haematological malignancies. Swiss Med Wkly 2014;144:w14050.
• 5 Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
• 6 Mellgren K, Hedegaard CJ, Schmiegelow K, Müller K. Plasma cytokine profiles at diagnosis in pediatric patients with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2012;34:271-5.
• 7 Kalra M, Dinand V, Choudhary S, Sachdeva A, Yadav SP. Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia. Indian Pediatr 2013;50:659-62.
• 8 Leblebisatan G, Antmen B, Sasmaz I, Kilinç Y. Vascular endothelial growth factor levels in childhood acute lymphoblastic and myeloblastic leukemia. Indian J Hematol Blood Transfus 2012;28:24-8.
• 9 Koomagi R, Zintl F, Sauerbrey A, Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 2001;7:3381-4.
• 10 Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-401.
• 11 Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002;95:1923-30.
• 12 Sensebe L, Deschaseaux M, Li J, Herve P, Charbord P. The broad spectrum of cytokine gene expression by myoid cells from the human marrow microenvironment. Stem Cells 1997;15:133-43.
• 13 Horacek JM, Kupsa T, Vasatova M, Jebavy L, Zak P. Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:299-301.
• 14 Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J Clin Oncol 2011;29:591-9.
• 15 Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004;100:1884-91.
• 16 Yetgin S, Yenicesu I, Cetin M, Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 2001;42:83-8.
• 17 Aref S, Salama O, Shamaa S, El-Refaie M, Mourkos H. Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology 2007;12:319-24.
• 18 Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI; Children's Oncology Group. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: A report from children's oncology group study CCG-1962. Clin Cancer Res 2006;12:6978-84.
• 19 Chand R, Chandra H, Chandra S, Verma SK. Role of microvessel density and vascular endothelial growth factor in angiogenesis of hematological malignancies. Bone Marrow Res 2016;2016:5043483.
• 20 Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-21.
• 21 Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-13.